Related references
Note: Only part of the references are listed.HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
Keiko Tanimura et al.
NPJ PRECISION ONCOLOGY (2022)
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer
Keiko Tanimura et al.
CANCER LETTERS (2021)
Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization
Lisa M. McGinnis et al.
JOURNAL OF PATHOLOGY (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea et al.
CANCER DISCOVERY (2021)
Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
Patrick C. Lee et al.
CANCERS (2021)
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer
Kota Ishioka et al.
CANCER RESEARCH (2021)
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
Masashi Mikubo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
Mikkel G. Terp et al.
NPJ PRECISION ONCOLOGY (2021)
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kari J. Kurppa et al.
CANCER CELL (2020)
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Kazuhiko Nakagawa et al.
LUNG CANCER (2020)
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
Takahiro Tsuji et al.
NATURE COMMUNICATIONS (2020)
Genomics-guided pre-clinical development of cancer therapies
Hayley E. Francies et al.
NATURE CANCER (2020)
FGF/FGFR signaling pathway involved resistance in various cancer types
Yangyang Zhou et al.
JOURNAL OF CANCER (2020)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
A novel HER2 gene body enhancer contributes to HER2 expression
Q. Liu et al.
ONCOGENE (2018)
Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling
Yanmei Yi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
Jingjing Xiao et al.
BMC CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
Jimin Yuan et al.
ONCOGENE (2018)
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Satoshi Yoda et al.
CANCER DISCOVERY (2018)
Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer
Andrew D. Jenks et al.
CELL REPORTS (2018)
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Rajeswara Rao Arasada et al.
NATURE COMMUNICATIONS (2018)
On a Square-Root Transformation of the Odds Ratio for a Common Outcome
Tyler J. VanderWeele
EPIDEMIOLOGY (2017)
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P. S. Perera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
K. R. Jakobsen et al.
ONCOGENESIS (2017)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification
Koh Furugaki et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation
Yasushi Yoshimura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon
Claire Rooney et al.
PLOS ONE (2016)
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini et al.
EMBO REPORTS (2015)
Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer
Liping Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
Millie Das et al.
LUNG CANCER (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Kai Hung Tiong et al.
APOPTOSIS (2013)
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
K. E. Ware et al.
ONCOGENESIS (2013)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer
Ken Takezawa et al.
CLINICAL CANCER RESEARCH (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Lindsay Marek et al.
MOLECULAR PHARMACOLOGY (2009)
Share Paper
